Anouk Donners

121 Systematic review on PK of emicizumab 46. Berro M, Elichiry M, Wasen K, Insagaray J, Rodríguez I. Use of ultrasound for evaluation of painful joint episodes perceived as haemarthrosis in adult patients with severe haemophilia. Haemophilia. 2018; 24: e124-125. 47. Rind D. ICER report - Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value. Evidence report. CEPAC 2018; 1-116. 48. Nardi MA. Emicizumab and the clinical laboratory. American Society for Clinical Laboratory Science. 2020; 32. 49. Coppola A, Castaman G, Santoro RC, Mancuso ME, Franchini M, Marino R, Rivolta GF, Santoro C, Zanon E, Sciacovelli L, Manca S, Lubrano R, Golato M, Tripodi A, Rocino A, Bernardini S, Biasoli C, Borchiellini A, Cultrera D, De Cristofaro R, et al. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia. 2020; 26: 937-945. 50. Bowyer A, Kitchen S, Maclean R. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia. 2020; 26: 536-542. 51. Donners A, Gerencsér L, van der Elst K, Fischer K, Urbanus R, El Amrani M. Mass spectrometry for the quantification of emicizumab in plasma of haemophilia A patients. Res Pract Thromb Haemost. 2022; 6 :e12725. 52. Callaghan MU, Negrier CG, Paz-Priel I, Chang TY-C, Chebon S, Lehle M, Mahlangu JN, Young G, KruseJarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2020; 137:2231-2242. 53. Siddaway AP, Wood AM, Hedges L V. How to Do a Systematic Review: A Best Practice Guide for Conducting and Reporting Narrative Reviews, Meta-Analyses, and Meta-Syntheses. Annu Rev Psychol. 2019; 70: 747-770. 6

RkJQdWJsaXNoZXIy MTk4NDMw